ClinicalTrials.gg
CompletedNCT05813275Updated Sep 11, 2026Results posted

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

A Phase 3 interventional study of AD109 and Placebo in OSA, sponsored by Apnimed. Completed at 73 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Apnimed · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
646
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive by Apnimed — 1 open to participants now, 1 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Apnimed.

Enrollment
3rd of 13
646 · median 60
Started
2023
with 2 others
Phase 3
3 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, this one is the 3rd largest by enrollment, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 11th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

1 of the 13 studies in Sleep Apnea, Obstructive by Apnimed is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by Apnimed, or all of them as a file.
02

Study summary

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.

03

Conditions studied

  • OSA

Keywords

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. ≥18 years of age at the time of .
  2. PSG criteria: AHI of ≥10 and ≤45; ≤ 25% central or mixed apneas; and PLM arousal index ≤15
  3. PROMIS-Fatigue: raw score ≥17
  4. PAP intolerance or current PAP refusal.
  5. between 18.5 and 40 kg/m2 for men, or 42 kg/m2 for women, inclusive.

Exclusion Criteria:

  1. Narcolepsy, restless leg syndrome, REM sleep behavior disorder
  2. Insomnia disorder characterized by difficulty initiating or maintaining sleep, or use within the past month of sedative-hypnotics or other medication for the purpose of treating or avoiding insomnia symptoms.
  3. Pierre Robin, Treacher Collins, or other craniofacial malformation syndrome, or grade ≥3 tonsillar hypertrophy.
  4. cardiac disease, e.g., ventricular arrhythmia, untreated or unstable coronary artery disease, cardiac failure. Stable atrial arrhythmia is allowed.
  5. Neuromuscular disorder (e.g., motor neuron disease, muscular dystrophy or myopathy, myasthenic syndrome); epilepsy; Parkinson, Alzheimer, or other neurodegenerative disease.

Exclusion Criteria:

-

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
646 participants (actual)

Study arms

  • Experimental
    AD109

    Drug: AD109

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugAD109

    Aroxybutynin 2.5 mg/atomoxetine 75 mg tablet, administered orally once daily at bedtime (Weeks 2-26). Week 1 run-in: aroxybutynin 2.5 mg/atomoxetine 37.5 mg tablet.

  • DrugPlacebo

    Matching placebo tablet administered orally once daily at bedtime for 26 weeks, with run-in and target dose matched to active arm packaging

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Apnea-Hypopnea Index (AHI)

    AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.

    Time frame: 6 months

07

Results

Posted Sep 11, 2026

Participant flow

Participant flow — Overall Study
MilestoneAD109Placebo
Started324322
Completed269276
Not completed5546
Withdrew: Adverse event41
Withdrew: Lost to follow-up1515
Withdrew: Physician decision22
Withdrew: Withdrawal by subject2122
Withdrew: Site terminated by sponsor82
Withdrew: Other/not reported54

Outcome measures

PrimaryChange From Baseline in Apnea-Hypopnea Index (AHI)

AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.

Time frame:
6 months
Reported as:
Least squares mean · events/hr
Change From Baseline in Apnea-Hypopnea Index (AHI)
events/hrAD109Placebo
Primary Full Analysis Set (Treatment Policy Estimand)-3.28 (-5.05 to -1.51)0.71 (-1.01 to 2.44)
While-on-Treatment population-6.11 (-7.80 to -4.41)0.44 (-1.15 to 2.02)
Statistical analysis
  • AD109 vs Placebo · Mixed Model Repeated Measures (MMRM) · p = 0.001 · Least squares mean difference: -3.99 · 95% CI -6.40 to -1.59
  • AD109 vs Placebo · Mixed Model Repeated Measures (MMRM) · p = <0.0001 · Least squares mean difference: -6.54 · 95% CI -8.80 to -4.28

Adverse events

Collected over from enrollment until end of follow-up, up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AD1090/325 (0%)5/325 (1.5%)176/325 (54.2%)
Placebo0/319 (0%)8/319 (2.5%)50/319 (15.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventAD109Placebo
CholelithiasisHepatobiliary disorders1/3251/319
Bile duct stoneHepatobiliary disorders0/3251/319
Pancreatitis acuteGastrointestinal disorders0/3251/319
Appendicitis perforatedInfections and infestations0/3251/319
AsthmaRespiratory, thoracic and mediastinal disorders1/3251/319
Respiratory failureRespiratory, thoracic and mediastinal disorders0/3251/319
Rib fractureInjury, poisoning and procedural complications0/3251/319
Road traffic accidentInjury, poisoning and procedural complications0/3251/319
Sternal fractureInjury, poisoning and procedural complications0/3251/319
Thoracic vertebral fractureInjury, poisoning and procedural complications0/3251/319
Most frequent other events
Most frequent other events
EventAD109Placebo
Dry mouthGastrointestinal disorders115/32529/319
Middle insomniaPsychiatric disorders38/32510/319
NauseaGastrointestinal disorders37/3252/319
Initial insomniaPsychiatric disorders30/3254/319
Urinary hesitationRenal and urinary disorders29/3251/319
ConstipationGastrointestinal disorders17/3254/319
SomnolenceNervous system disorders17/32510/319

Baseline characteristics

The Primary Full Analysis Set includes all participants who were not from the terminated site 1416, who were randomized into the main cohort and received at least 1 dose of IMP.

Age, Continuous
Age, Continuous(years)AD109PlaceboTotal
Mean57.5 ± 10.6757.1 ± 11.1157.3 ± 10.89
Sex: Female, Male
Sex: Female, Male(Participants)AD109PlaceboTotal
Female150153303
Male152160312
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AD109PlaceboTotal
American Indian or Alaska Native224
Asian232245
Native Hawaiian or Other Pacific Islander314
Black or African American5562117
White212216428
More than one race358
Unknown or Not Reported459
Baseline AHI4 group
Baseline AHI4 group(Participants)AD109PlaceboTotal
<15105109214
15 - 30125134259
>307270142
Baseline AHI4
Baseline AHI4(events/hr)AD109PlaceboTotal
Mean22.13 ± 11.81921.47 ± 10.60721.79 ± 11.214
08

Study locations

73 sites
  • Alabama Neurology &amp; Sleep Medicine
    Tuscaloosa, Alabama 35406, United States
  • Desert Clinical Research - CCT Research
    Mesa, Arizona 85213, United States
  • Foothills Research Center - CCT Research
    Phoenix, Arizona 85044, United States
  • Fiel Family Sports Medicine - PC CCT Research
    Tempe, Arizona 85283, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Preferred Research Partners, Inc.
    Little Rock, Arkansas 72211, United States
  • Orange County Research Institute
    Anaheim, California 92801, United States
  • North County Neurology Associates
    Carlsbad, California 92011, United States
  • Core Healthcare Group
    Cerritos, California 90703, United States
  • Exalt Clinical Research
    Chula Vista, California 91910, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • Probe Clinical Research Corporation
    Riverside, California 92501, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • Sleep Medicine Specialists of California
    San Ramon, California 94583, United States
  • SDS Clinical Trials Inc.
    Santa Ana, California 92705, United States
  • Provideré Research Inc.
    West Covina, California 91790, United States
  • Meris Clinical Research
    Brandon, Florida 33511, United States
  • Nouvelle Clinical Research
    Cutler Bay, Florida 33189, United States
  • Accel Research Sites
    DeLand, Florida 32720, United States
  • Research Centers of America, LLC
    Hollywood, Florida 33024, United States
  • Canvas Clinical Research
    Lake Worth, Florida 33467, United States
  • Florida Lung and Sleep Associates
    Lehigh Acres, Florida 33971, United States
  • Advanced Medical Research Institute
    Miami, Florida 33174, United States
  • Clinical Site Partners
    Miami, Florida 33186, United States
  • Clinical Neuroscience Solutions, Inc - Orlando
    Orlando, Florida 32801, United States
  • JSV Clinical Research Study Inc
    Tampa, Florida 33634, United States
  • Florida Pediatric Research Institute
    Winter Park, Florida 32789, United States
  • Atlanta Center for Medical Research, LLC
    Atlanta, Georgia 30031, United States
  • NeuroTrials Research
    Atlanta, Georgia 30342, United States
  • Georgia Neurology and Sleep Medicine Assoc
    Suwanee, Georgia 30024, United States
  • Javarra Inc-Privia Medical Group
    Thomasville, Georgia 31792, United States
  • St. Lukes Clinic - Idaho Pulmonary Associates
    Meridian, Idaho 83642, United States
  • Chicago Research Center Inc
    Chicago, Illinois 60634, United States
  • OSF HealthCare Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • The University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Advanced ENT and Allergy
    Louisville, Kentucky 40220, United States
  • Centennial Medical Group
    Elkridge, Maryland 21075, United States
  • Infinity Medical Research
    North Dartmouth, Massachusetts 02747, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Revive Research Institute
    Lathrup Village, Michigan 48076, United States
  • Las Vegas Clinical Trials
    North Las Vegas, Nevada 89030, United States
  • Neurology Specialists of Monmouth County
    West Long Branch, New Jersey 07764, United States
  • Javara Inc - Tryon Medical Partners PLCC
    Charlotte, North Carolina 28210, United States
  • Research Carolina Elite
    Denver, North Carolina 28025, United States
  • Peters Medical Research, LLC
    High Point, North Carolina 27260, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Sleep Management Institute (Intrepid)
    Cincinnati, Ohio 45245, United States
  • UC Health Sleep Medicine
    Cincinnati, Ohio 45267, United States
  • University Hospital of Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Abington Neurological Associate
    Abington, Pennsylvania 19001, United States
  • Respiratory Specialists
    Wyomissing, Pennsylvania 19610, United States
  • Tribe Clinical Research LL
    Greenville, South Carolina 29607, United States
  • OnSite Clinical Solutions LLC/Carolina Cardiology Associates P.A
    Rock Hill, South Carolina 29732, United States
  • Chattanooga Research &amp; Medicine, PLLC
    Chattanooga, Tennessee 37404, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • The Heights Hospital (HD Heights)
    Houston, Texas 77008, United States
  • Weill Cornell Medical College
    Houston, Texas 77030, United States
  • Lone Star Lung and Sleep Clinic
    Houston, Texas 77070, United States
  • Huntsville Research Institute LLC
    Huntsville, Texas 77340, United States
  • Epic Medical Research
    Red Oak, Texas 75154, United States
  • Element Research Group
    San Antonio, Texas 78229, United States
  • South Ogden Family Medicine / CCT Research
    South Ogden, Utah 84405, United States
  • Canadian Sleep Consultants
    Calgary, Alberta T2Z 3R6, Canada
  • Medical Arts Health Research
    Kelowna, British Columbia V1Y 9N7, Canada
  • AMNDX
    Markham, Ontario L3R 1A3, Canada
  • West Ottawa Sleep Centre
    Ottawa, Ontario K2C 0P7, Canada
  • Canadian Phase Onward Inc.
    Toronto, Ontario M3J 0K2, Canada
  • Toronto Sleep Institute
    Toronto, Ontario M4P 1P2, Canada
  • Sleep and Alertness Center
    Toronto, Ontario M5S 3A3, Canada
  • McGill University Health Centre
    Montreal, Quebec QC H4A, Canada
09

References and documents

Publications

  • Strollo PJ Jr, Farkas R, Taranto-Montemurro L, Cronin J, Patel SR; SynAIRgy Investigators. Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy). Am J Respir Crit Care Med. 2026 Jul 1;212(7):1569-1584. doi: 10.1093/ajrccm/aamag215. PubMed 42148495 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Mar 2025, 17 months.

Results were first posted in Sep 2026, 1 year 6 months after primary completion.

Of 27 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2023
First posted
Apr 14, 2023
StartActual
Sep 16, 2023
Primary completionActual
Mar 10, 2025
CompletionActual
Mar 14, 2025
Results first posted
Sep 11, 2026
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05813275
Lead sponsor
Apnimed
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
Sep 16, 2023
Primary completion
Mar 10, 2025
Completion
Mar 14, 2025
Results posted
Sep 11, 2026
Last update
Sep 11, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AD109

Start the discussion